Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion.

@article{Querques2013RepeatedID,
  title={Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion.},
  author={Lea Querques and Giuseppe Querques and Rosangela Lattanzio and Silvia Rita Gigante and Claudia Del Turco and Giulia Corradetti and Maria Lucia Cascavilla and Francesco Bandello},
  journal={Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde},
  year={2013},
  volume={229 1},
  pages={21-5}
}
PURPOSE To evaluate the effects of repeated intravitreal dexamethasone implant (IDI) (Ozurdex®) in eyes with macular edema (ME) due to retinal vein occlusion (RVO). METHODS We reviewed the charts of patients with RVO-related ME, who received repeated Ozurdex IDI (0.7 mg) on an 'as-needed' basis. Main outcome measures included changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), retreatment interval, and incidence of side effects. RESULTS A total of 33 eyes were… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde • 2018

Dexamethasone Intravitreal Implant for Early Treatment and Retreatment of Macular Edema Related to Branch Retinal Vein Occlusion: The Multicenter COBALT Study.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde • 2018

Pharmacologic Therapy of Ocular Disease

Handbook of Experimental Pharmacology • 2017

Similar Papers

Loading similar papers…